This inventor holds 1 USPTO granted patent and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: British Columbia Cancer Agency Branch, Fundacio Clinic, Hospital Clinic. Active years: 2012.
Company Filing History:
1 out of 66 
1 out of 2 
1 out of 1 
Years Active: 2012
Title: The Innovative Contributions of Erlend Smeland
Introduction
Erlend Smeland is a notable inventor based in Oslo, Norway. He has made significant contributions to the field of medical diagnostics, particularly in the area of lymphomas. His work focuses on utilizing gene expression data to improve the identification and prognosis of lymphoproliferative disorders.
Latest Patents
Erlend Smeland holds a patent for "Methods for identifying, diagnosing, and predicting survival of lymphomas." This invention provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. The patent discloses methods for identifying and predicting survival in lymphomas based on gene expression patterns. It introduces the Lymph Dx microarray, which is designed to obtain gene expression data from lymphoma samples. This innovative approach allows for the determination of the identity of specific lymphomas and aids in predicting survival outcomes for patients.
Career Highlights
Throughout his career, Erlend Smeland has worked with prestigious organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and the University of Nebraska. His experience in these institutions has contributed to his expertise in medical research and diagnostics.
Collaborations
Erlend has collaborated with esteemed colleagues, including Louis M. Staudt and George Wright. These partnerships have further enhanced the impact of his research and innovations in the field.
Conclusion
Erlend Smeland's contributions to the field of lymphoma diagnostics through his innovative patent demonstrate the importance of gene expression data in improving patient outcomes. His work continues to influence the development of more effective therapeutic approaches for lymphoproliferative disorders.